JP7890301B2 - 治療用放射線標識コンジュゲート及び治療におけるそれらの使用 - Google Patents

治療用放射線標識コンジュゲート及び治療におけるそれらの使用

Info

Publication number
JP7890301B2
JP7890301B2 JP2023547721A JP2023547721A JP7890301B2 JP 7890301 B2 JP7890301 B2 JP 7890301B2 JP 2023547721 A JP2023547721 A JP 2023547721A JP 2023547721 A JP2023547721 A JP 2023547721A JP 7890301 B2 JP7890301 B2 JP 7890301B2
Authority
JP
Japan
Prior art keywords
compound
gsao
nodaga
therapeutic
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023547721A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023547954A5 (cg-RX-API-DMAC7.html
JP2023547954A (ja
Inventor
フィリップ・ホグ
イヴァン・ホ・ション
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The University of Sydney
Original Assignee
The University of Sydney
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020903727A external-priority patent/AU2020903727A0/en
Application filed by The University of Sydney filed Critical The University of Sydney
Publication of JP2023547954A publication Critical patent/JP2023547954A/ja
Publication of JP2023547954A5 publication Critical patent/JP2023547954A5/ja
Application granted granted Critical
Publication of JP7890301B2 publication Critical patent/JP7890301B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023547721A 2020-10-14 2021-10-14 治療用放射線標識コンジュゲート及び治療におけるそれらの使用 Active JP7890301B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020903727 2020-10-14
AU2020903727A AU2020903727A0 (en) 2020-10-14 Conjugates and their use in therapy
PCT/AU2021/051203 WO2022077068A1 (en) 2020-10-14 2021-10-14 Therapeutic radiolabelled conjugates and their use in therapy

Publications (3)

Publication Number Publication Date
JP2023547954A JP2023547954A (ja) 2023-11-14
JP2023547954A5 JP2023547954A5 (cg-RX-API-DMAC7.html) 2024-10-25
JP7890301B2 true JP7890301B2 (ja) 2026-07-14

Family

ID=81207378

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023547721A Active JP7890301B2 (ja) 2020-10-14 2021-10-14 治療用放射線標識コンジュゲート及び治療におけるそれらの使用

Country Status (10)

Country Link
US (1) US20230398240A1 (cg-RX-API-DMAC7.html)
EP (1) EP4228710A4 (cg-RX-API-DMAC7.html)
JP (1) JP7890301B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230130610A (cg-RX-API-DMAC7.html)
CN (1) CN116472068A (cg-RX-API-DMAC7.html)
AU (1) AU2021359638A1 (cg-RX-API-DMAC7.html)
CA (1) CA3195410A1 (cg-RX-API-DMAC7.html)
IL (1) IL302033A (cg-RX-API-DMAC7.html)
MX (1) MX2023004327A (cg-RX-API-DMAC7.html)
WO (1) WO2022077068A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220152229A1 (en) 2019-04-12 2022-05-19 Centenary Institute Of Cancer Medicine And Cell Biology Conjugates and their use as imaging agents
US20250269072A1 (en) * 2021-10-14 2025-08-28 Centenary Institute Of Cancer Medicine And Cell Biology Processes for preparing radiolabelled conjugates

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016153054A1 (ja) 2015-03-25 2016-09-29 富士フイルム株式会社 新規な含窒素化合物またはその塩の製造方法およびそれらの製造中間体
JP7692839B2 (ja) 2019-04-12 2025-06-16 センテナリ インスティチュート オブ キャンサー メディシン アンド セル バイオロジー コンジュゲート及びそのイメージング剤としての使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100418585C (zh) * 2003-07-24 2008-09-17 伯拉考成像股份公司 稳定的放射性药物组合物及制备方法
WO2016088116A1 (en) * 2014-12-05 2016-06-09 University Health Network Use of antioxidants as radio-protective agents
US20160367620A1 (en) * 2015-06-19 2016-12-22 Harry B. Demopoulos Glutathione

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016153054A1 (ja) 2015-03-25 2016-09-29 富士フイルム株式会社 新規な含窒素化合物またはその塩の製造方法およびそれらの製造中間体
JP7692839B2 (ja) 2019-04-12 2025-06-16 センテナリ インスティチュート オブ キャンサー メディシン アンド セル バイオロジー コンジュゲート及びそのイメージング剤としての使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Bogdan Mitran et al.,Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist 177Lu-DOTAGA-PEG2-RM26,International Journal of Cancer,145,2019年,3347-3358
Ivan Ho Shon, et al.,Preparation of a Dithiol-Reactive Probe for PET Imaging of Cell Deat,Hogg, P. (eds) Functional Disulphide Bonds. Methods in Molecular Biology,vol. 1967,2019年,295-304

Also Published As

Publication number Publication date
CN116472068A (zh) 2023-07-21
IL302033A (en) 2023-06-01
KR20230130610A (ko) 2023-09-12
US20230398240A1 (en) 2023-12-14
MX2023004327A (es) 2023-08-30
CA3195410A1 (en) 2022-04-21
EP4228710A4 (en) 2025-04-09
EP4228710A1 (en) 2023-08-23
WO2022077068A1 (en) 2022-04-21
JP2023547954A (ja) 2023-11-14
AU2021359638A1 (en) 2023-06-01

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241015

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241015

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250821

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260421

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260602

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260702

R150 Certificate of patent or registration of utility model

Ref document number: 7890301

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150